Clinical significance of miRNA-21, -103, -129, -150 in serous ovarian cancer

Wilczyński, Miłosz; Żytko, Ewelina; Danielska, Justyna; Szymańska, Bożena; Dzieniecka, Monika; Nowak, Marek; Malinowski, Jakub; Owczarek, Dariusz; Wilczyński, Jacek R.

doi:10.1007/s00404-018-4660-5

Cited by 9 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum miR-21 expression was found to be increased in EOC patients, and it may function as a novel marker for the diagnosis and prognosis of EOC (15). The expression of miR-150 is higher in primary serous OC than in omental metastases, and its lower expression is associated with shorter progression free-survival in metastatic tissues (16). Nevertheless, the miRNAs related to the recurrence of OC have not been fully revealed.…”

Section: Introductionmentioning

confidence: 99%

A 19‑miRNA Support Vector Machine classifier and a 6‑miRNA risk score system designed for ovarian cancer patients

Dong

2019

Oncol Rep

View full text Add to dashboard Cite

Ovarian cancer (OC) is the most common gynecologic malignancy with high incidence and mortality. The present study aimed to develop approaches for determining the recurrence type and identify potential miRNA markers for OC prognosis. The miRNA expression profile of OC (the training set, including 390 samples with recurrence information) was downloaded from The Cancer Genome Atlas database. The validation sets GSE25204 and GSE27290 were obtained from the Gene Expression Omnibus database. Prescreening of clinical factors was conducted using the survival package, and the differentially expressed miRNAs (DE-miRNAs) were identified using the limma package. Using the Caret package, the optimal miRNA set was selected to build a Support Vector Machine (SVM) classifier. The miRNAs and clinical factors independently related to prognosis were analyzed using the survival package, and the risk score system was constructed. Finally, the miRNA-target regulatory network was built by Cytoscape software, and enrichment analysis was performed. There were 46 DE-miRNAs between the recurrent and non-recurrent samples. After the optimal 19-miRNA set was selected for constructing the SVM classifier, 6 DE-miRNAs (miR-193b, miR-211, miR-218, miR-505, miR-508 and miR-514) independently related to prognosis were further extracted to build the risk score system. The neoplasm cancer status was independently correlated with the prognosis and conducted with stratified analysis. Additionally, the target genes in the regulatory network were enriched in the regulation of actin cytoskeleton and the TGF-β signaling pathway. The 6-miRNA signature may serve as a potential biomarker for OC prognosis, particularlyfor recurrence.

show abstract

Section: Introductionmentioning

confidence: 99%

A 19‑miRNA Support Vector Machine classifier and a 6‑miRNA risk score system designed for ovarian cancer patients

Dong

2019

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…MiRNA-150 can be a prognostic factor in advanced OC. 19 The combined monitoring of serum miR-26b and miR-21 is of value in the clinical management of OC. 20 MiR-27a is an oncogenic molecule and prognostic factor in patients with OC.…”

Section: Discussionmentioning

confidence: 99%

Expression, Clinical Significance, and Prospective Pathway Signaling of miR-501-3p in Ovarian Cancer Based on Database and Informatics Analysis

Chen

Jin

Wang

et al. 2021

IJGM

View full text Add to dashboard Cite

Background The present study aims to explore the expression, clinical significance, and prospective pathway signaling of miR-501-3p in ovarian cancer (OC) based on database and informatics analysis. Methods Kruskal–Wallis test, Wilcoxon sign-rank test, and logistic regression were used to evaluate the relationship between clinical features and miR-501-3p expression. Kaplan–Meier survival curve analysis was used to explore the relationship between miR-501-3p expression and the prognosis of OC patients. The miRNA targets were obtained from databases TargetScan, miRanda, TarBase, miRTarBase, miR2Disease, miRecords, and miRWalk. GO and KEGG analyses were used to analyze the significant involvement of miR-501-3p target genes in function. Results The low miR-501-3p expression in OC was significantly associated with histologic grade (P=0.015). Low miR-501-3p expression predicted a poorer overall survival (HR: 0.77; 95% CI: 0.61–0.96; P=0.02) and disease-specific survival (HR: 0.77; 95% CI: 0.61–0.99; P=0.038). GO and KEGG analyses demonstrated that miR-501-3p might participate in the development of OC by pathways including one carbon pool by folate, protein digestion and absorption, cell cycle, kaposi sarcoma-associated herpesvirus infection, and viral carcinogenesis. Conclusions Low miR-501-3p expression is significantly associated with poor survival in OC patients. It may be a promising prognostic biomarker for OC patients.

show abstract

“…Only a few authors have assessed MiRNA-103 expression levels in ovarian cancer. Wilczynski et al assessed miRNA-103 by qRT-PCR in 48 samples derived from advanced serous ovarian cancer patients and found no differences between primary tumor and healthy ovarian tissue [ 20 ]. Yang et al performed qRT-PCR to compare miR-103 expression levels in ovarian cancer and healthy ovarian tissues, however, they used only five fresh tissue samples of serous ovarian cancer [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

MiRNA-103/107 in Primary High-Grade Serous Ovarian Cancer and Its Clinical Significance

Wilczyński

Kiełbik

Senderowska

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

High levels of miRNA-103/107 are associated with poor outcomes in the case of breast cancer patients. MiRNA-103/107-DICER axis may be one of the key regulators of cancer aggressiveness. MiRNA-103/107 expression levels have never been related to patients’ clinicopathological data in epithelial ovarian cancer. We aimed to assess miRNA-103/107 expression levels in high grade serous ovarian cancer tissues. Expression levels of both miRNAs were related to the clinicopathological features and survival. We also evaluated expression levels of miRNA-103/107 and DICER in selected ovarian cancer cell lines (A2780, A2780cis, SK-OV-3, OVCAR3). We assessed the relative expression of miRNA-103/107 (quantitative reverse transcription-polymerase chain reaction) in fifty archival formalin-fixed paraffin-embedded tissue samples of primary high grade serous ovarian cancer. Then, miRNA-103/107 and DICER expression levels were evaluated in selected ovarian cancer cell lines. Additionally, DICER, N-/E-cadherin protein levels were assessed with the use of western blot. We identified miRNA-107 up-regulation in ovarian cancer in comparison to healthy tissues (p = 0.0005). In the case of miRNA-103, we did not observe statistically significant differences between cancerous and healthy tissues (p = 0.07). We did not find any correlations between miRNA-103/107 expression levels and clinicopathological features. Kaplan–Meier survival (disease-free and overall survival) analysis revealed that both miRNAs could not be considered as prognostic factors. SK-OV-3 cancer cell lines were characterized by high expression of miRNA-103/107, relatively low expression of DICER (western-blot), and relatively high N-cadherin levels in comparison to other ovarian cancer cell lines. Clinical and prognostic significance of miRNA-103/107 was not confirmed in our study.

show abstract

Clinical significance of miRNA-21, -103, -129, -150 in serous ovarian cancer

Cited by 9 publications

References 34 publications

A 19‑miRNA Support Vector Machine classifier and a 6‑miRNA risk score system designed for ovarian cancer patients

A 19‑miRNA Support Vector Machine classifier and a 6‑miRNA risk score system designed for ovarian cancer patients

Expression, Clinical Significance, and Prospective Pathway Signaling of miR-501-3p in Ovarian Cancer Based on Database and Informatics Analysis

MiRNA-103/107 in Primary High-Grade Serous Ovarian Cancer and Its Clinical Significance

Contact Info

Product

Resources

About